Mr.k. Christopher Garcia

Biography

Dr. Garcia is a leading scientist studying the structural biology of immune receptor recognition and activation and receptor signaling mechanisms using protein engineering. Dr. Garcia’s laboratory has a longstanding interest in the structural biology of adaptive immunity and is mainly focused on understanding how the T cell receptor recognizes MHC molecules. Dr. Garcia was elected to the National Academy of Sciences in 2012. Since 1999, he has been a Professor in the Department of Molecular and Cellular Physiology and Department of Structural Biology at Stanford University School of Medicine. In addition, Dr. Garcia is an Investigator with the Howard Hughes Medical Institute. Dr. Garcia is one of the inventors who discovered soluble versions of the signal regulatory protein-α (SIRPα) that have been engineered to bind CD47 with significantly greater affinity than natural SIRPα, which has provided the founding technology for Alexo Therapeutics. Dr. Garcia is a leading scientist studying the structural biology of immune receptor recognition and activation and receptor signaling mechanisms using protein engineering. Dr. Garcia’s laboratory has a longstanding interest in the structural biology of adaptive immunity and is mainly focused on understanding how the T cell receptor recognizes MHC molecules. Dr. Garcia was elected to the National Academy of Sciences in 2012. Since 1999, he has been a Professor in the Department of Molecular and Cellular Physiology and Department of Structural Biology at Stanford University School of Medicine. In addition, Dr. Garcia is an Investigator with the Howard Hughes Medical Institute. Dr. Garcia is one of the inventors who discovered soluble versions of the signal regulatory protein-α (SIRPα) that have been engineered to bind CD47 with significantly greater affinity than natural SIRPα, which has provided the founding technology for Alexo Therapeutics.

Research Interest

structural biology of adaptive immunity